Last reviewed · How we verify
Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation
Carboplatin is widely used for conditioning regimens of autologous hematopoietic stem cell transplantation for pediatric solid tumor, but the pharmacokinetics has not been evaluated in pediatric stem cell transplantation before. As carboplatin have renal toxicity, the pharmacokinetic study of carboplatin would help the safe and effective administration of carboplatin for transplantation patients. Especially, the dose of carboplatin is higher at conditioning chemotherapy, resulting in higher toxicity. Carboplatin is a drug mostly excreted by kidney, and the dose of carboplatin is recommended according to the body surface area and kidney function, represented by glomerular filtration rate. After analyzing the pharmacokinetics of carboplatin, analyses will also be done for the methods to determine the appropriate carboplatin dose.
Details
| Lead sponsor | The Korean Society of Pediatric Hematology Oncology |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 24 |
| Start date | 2015-01 |
| Completion | 2016-12 |
Conditions
- Pediatric Solid Tumor
Interventions
- Carboplatin
Primary outcomes
- Area Under Curve (AUC) of carboplatin at the first and last administration day — From the start of first dose carboplatin administration to 5 hours from the last administration
Countries
South Korea